JPH0464703B2 - - Google Patents
Info
- Publication number
- JPH0464703B2 JPH0464703B2 JP59137225A JP13722584A JPH0464703B2 JP H0464703 B2 JPH0464703 B2 JP H0464703B2 JP 59137225 A JP59137225 A JP 59137225A JP 13722584 A JP13722584 A JP 13722584A JP H0464703 B2 JPH0464703 B2 JP H0464703B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- plasma
- depressions
- mixture
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 9
- 229960002684 aminocaproic acid Drugs 0.000 claims description 9
- 229920000159 gelatin Polymers 0.000 claims description 9
- 239000008273 gelatin Substances 0.000 claims description 9
- 235000019322 gelatine Nutrition 0.000 claims description 9
- 235000011852 gelatine desserts Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000037311 normal skin Effects 0.000 claims description 2
- -1 plasma Substances 0.000 claims 2
- 239000011344 liquid material Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 9
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- 208000032544 Cicatrix Diseases 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000037387 scars Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Description
【発明の詳細な説明】
本発明は、尋常性〓瘡、帯状疱疹、単純疱疹、
水痘等の起因する卵形皮膚陥凹、並びに外科術後
瘢痕、外傷痕瘢痕、しわ等の線状皮膚陥凹の修復
に有用な組成物と、それによる皮膚陥凹修復方法
に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention is applicable to acne vulgaris, herpes zoster, herpes simplex,
The present invention relates to a composition useful for repairing oval skin depressions caused by chickenpox, etc., and linear skin depressions such as post-surgical scars, trauma scars, and wrinkles, and a method for repairing skin depressions using the composition.
さらに詳細に言うと、本発明は、アミノカプロ
ン酸と吸水性ゼラチンスポンジ微粉末とを、特定
の割合で、血漿または生理食塩水と混合した物を
使つて、目的の効果を得る方法に関する。 More specifically, the present invention relates to a method of obtaining a desired effect using a mixture of aminocaproic acid and water-absorbing gelatin sponge fine powder in a specific ratio with blood plasma or physiological saline.
尋常性〓瘡に関連するような皮膚陥凹は、これ
までは、色々な方法で修復がされてきており、中
でも最も重要なのが、皮膚挫傷法である。 Skin depressions such as those associated with acne vulgaris have been repaired by various methods, the most important of which is the skin contusion method.
この方法は、しばしば過剰の流血を生じ、かつ
治療が長引くのが通例である。傷部位が治癒し
て、修復効果を評価するのに、約２週間以上待た
なければならず、しかも、この方法では、時折治
癒後に傷跡が残るか、あるいは望ましくない色素
物変化が生じることがわかつている。 This method often results in excessive blood loss and treatment is typically prolonged. One has to wait approximately two weeks or more for the wound site to heal and assess the effectiveness of the repair, and this method sometimes leaves behind a scar or produces undesirable pigment changes after healing. There used to be.
陥凹した傷跡を、外科的に除去する方法もある
が、これも、しばしば多くの時間を必要とし、か
つ痛みを伴うとともに、治癒後に、しばしば傷跡
が残る結果となる。 Surgical removal of depressed scars also exists, but these are often time consuming and painful, and often result in scarring after healing.
最近開発された牛コラーゲン移値法は、最初に
皮膚テストを行う必要があり、かつ何回も注入し
なければならず、また、コラーゲン物質は、低温
で保存することが必要であるという不利がある。
また、皮膚テストの結果が陰性であるにもかかわ
らず、患者が、アレルギー反応及び異体反応を起
こすことがある。 The recently developed bovine collagen transfer value method has the disadvantages of requiring an initial skin test and multiple injections, and that the collagen material must be stored at low temperatures. be.
Also, patients may develop allergic and foreign body reactions despite negative skin test results.
従つて、皮膚陥凹を修復するための、安全で、
効果的で、かつ整形的意図にかなう材料と方法が
要求されていることは明らかである。 Therefore, it is safe and effective for repairing skin depressions.
It is clear that there is a need for materials and methods that are both effective and cosmetically intended.
本発明の主要な目的は、従来利用されて来た方
法における欠点を克服し、かつ外科的除去や擦傷
を不要とする可能性のある、皮膚陥凹の修復に有
用な組成物と方法を提供することである。 A primary object of the present invention is to provide compositions and methods useful for repairing skin depressions that overcome the shortcomings of previously available methods and that may eliminate the need for surgical removal or abrasion. It is to be.
本発明の別の目的は、修復可能な卵形及び線形
陥凹損傷を、永久的に修復して、即時に、有益で
整形的目的にかなう効果を得ることを可能にする
組成物と方法を提供することである。 Another object of the present invention is to provide compositions and methods that allow repairable oval and linear pit lesions to be permanently repaired to obtain an immediate beneficial and orthopedic effect. It is to provide.
本発明の更にもう一つの目的は、皮膚陥凹の下
方に、容易に導入することができ、何回も注入す
る必要なく、新しいコラーゲン組織の成長を促進
する効力のある液状組成物の形に、効果的に調製
することができ、かつ室温での保存寿命が長い凍
結乾燥製剤を提供することである。 Yet another object of the present invention is to form an effective liquid composition that can be easily introduced under skin depressions and promotes the growth of new collagen tissue without the need for multiple injections. The object of the present invention is to provide a lyophilized formulation that can be effectively prepared and has a long shelf life at room temperature.
本発明によれば、100重量部の吸水性ゼラチン
スポンジ微粉末と、125重量部のアミノカプロン
酸を含む、皮膚陥凹の修復に有用な組成物が提供
される。 According to the present invention, there is provided a composition useful for repairing skin depressions, comprising 100 parts by weight of water-absorbing gelatin sponge micropowder and 125 parts by weight of aminocaproic acid.
この組成物は、吸水性ゼラチンスポンジ微粉末
と、アミノカプロン酸の混合物各225重量部に対
して(1)血漿５c.c.＋0.9重量％の塩化ナトリウムを
含む食塩水と、(2)1.0c.c.の生理食塩水のうち少く
とも一方を含んでいる。 This composition consists of (1) saline solution containing 5 c.c. of plasma + 0.9 wt. % sodium chloride, and (2) 1.0 wt. Contains at least one of cc physiological saline.
また、この組成物は、発明の好ましい実施例に
従つて、1.9mgのベンジルアルコールを含んでい
てもよい。 The composition may also contain 1.9 mg of benzyl alcohol, according to a preferred embodiment of the invention.
本明細書において使われている「皮膚陥凹」と
いう言葉は、(1)尋常性〓瘡、単純疱疹、帯状疱
疹、水痘、外傷及び手術に起因する卵形陥凹、並
びに、(2)外科術後瘢痕、外傷後瘢痕、しわ等の線
状皮膚陥凹を含むものである。 As used herein, the term "skin pit" refers to (1) oval pits caused by acne vulgaris, herpes simplex, shingles, chickenpox, trauma, and surgery; This includes postoperative scars, post-traumatic scars, and linear skin depressions such as wrinkles.
本明細書中で使用する血漿は、ヒトからとつた
ものであることが好ましく、本方法を実施して治
療しようとしている当の患者からとつたものであ
ると、更に好ましい。血漿は、準備段階である麻
酔時、又は陥凹瘢痕や、しわの下を堀る時に切開
した組織から採取したものであつてもよいし、静
脈血から分離したものであつてもよい。 Preferably, the plasma used herein is of human origin, more preferably of the patient to be treated by carrying out the method. Plasma may be collected from tissue incised during preparatory anesthesia or when excavating under depressed scars or wrinkles, or may be separated from venous blood.
反応を起こして、ついには、フイブリン形成
（血塊）へと導くのは、損傷波下組織部に存在し
ている血漿フイブリノゲンとトロンビンである。
このフイブリン中に、新たなコラーゲンを生成蓄
積する繊維芽細胞が侵入してくる。こうして、新
しい組織が生成される結果、陥凹は、正常レベル
へと、永久的に上昇させられるのである。 It is the plasma fibrinogen and thrombin present in the tissue beneath the injury that causes the reaction and ultimately leads to fibrin formation (blood clot).
Fibroblasts that produce and accumulate new collagen invade this fibrin. The depression is thus permanently elevated to its normal level as a result of new tissue generation.
本発明の目的とする効果を達成するために、本
発明液状組成物の0.1mlを、通例、皮下的に、１
箇所か２箇所の約３〜５mm直径の卵形損傷部位の
下方か、又は１箇所か２箇所の約３〜５mm長さ
で、約１〜２mm幅の線状損傷部位の下方へ導入す
る。 To achieve the desired effect of the present invention, 0.1 ml of the liquid composition of the present invention is typically administered subcutaneously for 1 hour.
It is introduced under one or two oval-shaped lesions about 3-5 mm in diameter, or under one or two linear lesions about 3-5 mm long and about 1-2 mm wide.
より大きい損傷部位は、それだけ、より多量の
血漿と組成物を必要とすることは当然である。 Naturally, larger sites of injury require larger amounts of plasma and composition.
静脈血から、血漿を分離する場合は、8.5c.c.の
患者静脈血を、1.5c.c.のACD（抗凝血性シトレー
トデキストロース）溶液と混合して、１分間に
2000回転のスピードで、約３〜10分間、遠心分離
すれば、血漿が得られる。 To separate plasma from venous blood, mix 8.5 cc of patient's venous blood with 1.5 cc of ACD (anticoagulant citrate dextrose) solution and separate it in 1 minute.
Plasma can be obtained by centrifugation at a speed of 2000 rpm for about 3 to 10 minutes.
こうして得られた血漿分画は、無菌試験管中に
収集して、引き続いて使用に供せられる。 The plasma fraction thus obtained is collected in a sterile test tube for subsequent use.
本発明の実施に際して使用されるアミノカプロ
ン酸は、次式
NH2CH2（CH2）4COOH又は
4NH2CH2（CH2）4COOH・CaX2
で表わされる化合物である。式中Ｘは、ハロゲン
の好ましくは塩素又は臭素、又は他の同様な作用
をする化合物である。 The aminocaproic acid used in the practice of the present invention is a compound represented by the following formula: NH 2 CH 2 (CH 2 ) 4 COOH or 4NH 2 CH 2 (CH 2 ) 4 COOH·C a X 2 . In the formula, X is a halogen, preferably chlorine or bromine, or another similarly acting compound.
アミノカプロン酸は、日本特許215676号及び同
215679号に従つて調製すればよい。アミノカプロ
ン酸は、フイブリンと、その前駆物質を破壊する
酵素プラスミンを阻害する働きをする。 Aminocaproic acid is disclosed in Japanese Patent No. 215676 and
It may be prepared according to No. 215679. Aminocaproic acid works by inhibiting the enzyme plasmin, which destroys fibrin and its precursors.
吸水性ゼラチンスポンジとしては、無菌で、水
に相当に不溶性であり、かつ非抗原性であり、し
かも、蛋白分解的に完全に消化されうるゼラチン
スポンジ微粉末を使用する。吸水性ゼラチンスポ
ンジ微粉末の調製法は、米国特許第2464357号明
細書に開示されている。 As the water-absorbing gelatin sponge, a gelatin sponge fine powder is used which is sterile, fairly insoluble in water, non-antigenic, and completely proteolytically digestible. A method for preparing water-absorbing gelatin sponge fine powder is disclosed in US Pat. No. 2,464,357.
この成分は、皮下物に皮膚陥凹下に導入された
後、フイブリンとその前駆物質を捕え、該陥凹の
下方におけるフイブリン形成を著しく増進させ
る。 After being introduced into the subcutaneous object below the skin recess, this component traps fibrin and its precursors and significantly enhances fibrin formation below the recess.
形成されたフイブリンが繊維芽細胞を引きつけ
ると、この繊維芽細胞は、フイブリンを吸い込ん
で、所望のコラーゲンと置き換えて、正常の皮膚
レベルまで、陥凹を修復する。 The formed fibrin attracts fibroblasts, which suck it up and replace it with the desired collagen, repairing the depression to the normal skin level.
Claims (1)
末と、約125重量％のアミノカプロン酸と、これ
らの混合物の各225重量％に対して、１mlの(1)0.9
重量％の塩化ナトリウムを含む食塩水溶液または
(2)血漿、あるいはこれら(1)と(2)の等量混合物のう
ちのいずれかを含んでなる、皮膚陥凹の修復に有
用な液状組成物であつて、皮膚陥凹の下方に注入
投与するための、上記アミノカプロン酸と吸水性
ゼラチンスポンジ微粉末を含む液状物質を生成す
るのに十分な量だけ、上記生理食塩水、血漿また
はこれらの混合物を含む組成物。 ２ 約100重量％の吸水性ゼラチンスポンジ微粉
末と、約125重量％のアミノカプロン酸と、これ
らの混合物の各225重量％に対して、１mlの(1)0.9
重量％の塩化ナトリウムを含む食塩水溶液または
(2)血漿、あるいはこれら(1)と(2)の等量混合物のう
ちのいずれかを含んでなる、皮膚陥凹の修復に有
用な液状組成物であつて、皮膚陥凹の下方に注入
投与するための、上記アミノカプロン酸と吸水性
ゼラチンスポンジ微粉末を含む液状物質を生成す
るのに十分な量だけ、上記生理食塩水、血漿また
はこれらの混合物を含む組成物を、新組織形成を
刺激するのに十分な量だけ、皮膚陥凹の下方に皮
内投与することにより、陥凹を正常皮膚レベルに
まで上昇させることを特徴とする皮膚陥凹修復方
法。[Claims] 1. About 100% by weight of water-absorbing gelatin sponge fine powder, about 125% by weight of aminocaproic acid, and 1 ml of (1)0.9 for each 225% by weight of the mixture.
saline solution containing % sodium chloride by weight or
(2) A liquid composition useful for repairing skin depressions, comprising either plasma or a mixture of equal amounts of (1) and (2), which is injected below the skin depressions. A composition comprising said saline, plasma, or a mixture thereof in an amount sufficient to produce a liquid material comprising said aminocaproic acid and a water-absorbing gelatin sponge micropowder for administration. 2 About 100% by weight of water-absorbing gelatin sponge fine powder, about 125% by weight of aminocaproic acid, and 1 ml of (1) 0.9 for each 225% by weight of these mixtures.
saline solution containing % sodium chloride by weight or
(2) A liquid composition useful for repairing skin depressions, comprising either plasma or a mixture of equal amounts of (1) and (2), which is injected below the skin depressions. administering a composition comprising said saline, plasma, or a mixture thereof in an amount sufficient to produce a liquid substance comprising said aminocaproic acid and a water-absorbing gelatin sponge micropowder to stimulate neotissue formation; 1. A method for repairing skin depressions, which comprises intradermally administering a sufficient amount below the skin depressions to raise the depressions to a normal skin level.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59137225A JPS6120549A (en) | 1984-07-04 | 1984-07-04 | Composition and method for repairing skin depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59137225A JPS6120549A (en) | 1984-07-04 | 1984-07-04 | Composition and method for repairing skin depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6120549A JPS6120549A (en) | 1986-01-29 |
| JPH0464703B2 true JPH0464703B2 (en) | 1992-10-15 |
Family
ID=15193700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59137225A Granted JPS6120549A (en) | 1984-07-04 | 1984-07-04 | Composition and method for repairing skin depression |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6120549A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4210231B2 (en) * | 2004-03-25 | 2009-01-14 | 株式会社資生堂 | Cosmetic method for improving skin wrinkles and wrinkle improving tool |
| DE102005054937A1 (en) * | 2005-11-17 | 2007-05-24 | Gelita Ag | Angiogenesis promoting substrate |
-
1984
- 1984-07-04 JP JP59137225A patent/JPS6120549A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6120549A (en) | 1986-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4061731A (en) | Compositions containing collagen and methods of use for repairing depressed cutaneous scars | |
| Warrell et al. | Poisoning by bites of the saw-scaled or carpet viper (Echis carinatus) in Nigeria | |
| US4879282A (en) | Medical application for heparin and related molecules | |
| KR100795654B1 (en) | Use of epidermal growth factor-containing pharmaceutical composition to prevent diabetic foot amputation | |
| JPH0813742B2 (en) | Anticoagulant | |
| Arata et al. | Effect of topical application of glycine and proline on recalcitrant leg ulcers of prolidase deficiency | |
| REISER et al. | Tryptic debridement of necrotic tissue | |
| JP3012319B2 (en) | Treatment of edema due to brain and muscle tissue injury | |
| US4302577A (en) | Process for preparing CSA or CSC | |
| Höltje | Successful replantation of an amputated upper lip | |
| Jamision et al. | LYSIS OF A SUPERIOR MESENTERIC ARTERY EMBOUS FOLLOWING LOCAL INFUSION OF STREPTOKINASE AND HEPARIN | |
| JPH06503319A (en) | Cell proliferation matrix and its use | |
| Fisher et al. | Partial rupture of the tendo calcaneus with heterotopic ossification: report of a case | |
| Wessler et al. | Theory and practice in acute venous thrombosis: a reappraisal | |
| JP3480737B2 (en) | Method for the treatment of scar tissue | |
| JPH0464703B2 (en) | ||
| Elkeles et al. | ABC of vascular diseases. The diabetic foot | |
| RU2003346C1 (en) | Composition for enzymic hydrolysis of protein | |
| Santos-Dias | CO2 laser surgery in hemophilia treatment | |
| SU1711896A1 (en) | Method for treating wounds not healing for a long time | |
| SMITH | Amputation through lower third of leg for diabetic and arteriosclerotic gangrene | |
| RU2093093C1 (en) | Method for treating deep frostbites in hand fingers | |
| MORANI | Trypsin therapy in the management of chronic surface ulcers | |
| RU2152815C1 (en) | Method for treating the cases of acute virus hepatitis | |
| RU2092121C1 (en) | Method for auto- and homoplastic skin transplantation |